R & D

Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Earlier and Advanced Stages of Non-Small Cell Lung Cancer

 This material is intended to notify the press release issued on June 3 (local time) by Bristol Myers Squibb, our license partner for Opdivo.
 Please click https://www.bms.com/media/press-releases.html for the original press release.